Peptide data sheet
Amycretin
GLP-1 · NNC0487-0111 · NN0487
Verdict
promisingfor metabolic and weight-related research endpoints
Quick answer
Amycretin is an investigational molecule from Novo Nordisk that activates two appetite-signaling pathways at once - the GLP-1 receptor and the amylin receptor - in a single compound available in early trials as both a tablet and an injection. It is commonly discussed for weight-related and metabolic endpoints, but it remains in early clinical study, is not FDA-approved, and is not available for human use.
- Class
- Unimolecular GLP-1 receptor and amylin receptor dual agonist (investigational)
- Half-life
- Reported as supporting once-weekly injectable and once-daily oral schedules in early trials
- FDA status
- Not FDA-approved; investigational, in early-phase clinical trials only
Which form actually works?
Injectable (subcutaneous, once-weekly)
Promising
The injectable form is the more-studied route in early trials; researchers reported meaningful reductions in body weight over the study window, but the data comes from small, short, early-phase cohorts.
Oral (tablet)
Promising
An oral peptide that survives the gut is unusual and part of why amycretin drew attention; the oral form is studied for the same metabolic endpoints, though human data is even more limited than the injectable.